Puma Biotech (PBYI) Reports Q3 EPS of $0.17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BofA/Merrill Lynch Downgrades Puma Biotechnology (PBYI) to Underperform
November 2, 2018 9:18 AM EDTBofA/Merrill Lynch analyst Ying Huang downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to Underperform with a price target of $25.00 (from $92.00).
The analyst cites weak Nerlynx sales for the dramatic reversal of opinion.
For an analyst ratings summary and ratings history... More
JPMorgan Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 5:55 AM EDTJPMorgan analyst Cory Kasimov downgraded Puma Biotechnology (NASDAQ: PBYI) from Neutral to Underweight with a price target of $23.00 (from $83.00).
The analyst is incrementally more negative citing the "significantly tempered" expectations on Nerlynx.
For an analyst ratings summary and ratings history on... More
Barclays Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 4:32 AM EDTBarclays analyst Gena Wang downgraded Puma Biotechnology (NASDAQ: PBYI) from Equalweight to Underweight with a price target of $29.00 (from $72.00).
The analyst steps aside citing the Q3 revenue miss along with a lack of growth clarity on Nerlynx.
For an analyst ratings... More
